TABLE 2 

Prevalence of pneumococcal nasopharyngeal colonization in PCV7-vaccinated and PCV-unvaccinated, HIV-uninfected children as measured by quantitative qPCR

PneumococcusaPrevalence in 9-mo-old
childrenb
OR (95% CI),
P valuec
aORd (95% CI),
P value
Prevalence in 16-mo-old
children
OR (95% CI),
P value
aOR (95% CI),
P value
PCV7-
unvaccinated
(n = 181)
PCV7-
vaccinated
(n = 175)
PCV7-
unvaccinated
(n = 193)
PCV7-
vaccinated
(n = 164)
lytA150 (82.9)125 (71.4)0.52 (0.31–0.86),
P = 0.01
0.45 (0.23–0.87),
P = 0.01
157 (81)123 (75)0.68 (0.41–1.14),
P = 0.147
0.55 (0.29–1.03),
P = 0.06
VT serotypes112 (61.9)63 (36)0.35 (0.21–0.58),
P < 0.001
0.37 (0.19–0.7),
P = 0.002
100 (51.8)54 (32.9)0.44 (0.27–7.01),
P < 0.001
0.41 (0.26–0.63),
P = 0.007
NVT serotypes54 (33.7)70 (40)1.74 (1.08–2.82),
P = 0.002
1.88 (1.02–3.48),
P = 0.02
73 (37.8)102 (62.2)1.81 (1.12–2.93),
P < 0.001
2.2 (1.18–4.1),
P = 0.01
  • a Streptococcus pneumoniae carrying the lytA gene or S. pneumoniae serotypes. PCV7 (7-valent pneumococcal conjugate vaccine) serotypes/serogroups (VT) include 4, 6A/B, 9A/L/N/V, 14, 18 A/B/C, 19B/F, and 23F. Nonvaccine serotypes/serogroups (NVT) are 1, 3, 5, 6 C/D, 7C, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15 A/B/C/F, 16F, 17F, 19A, 20, 21, 23A/B, and 34/37/17A.

  • b Prevalence of pneumococcal nasopharyngeal colonization in 9-month-old or 16-month-old children vaccinated or not vaccinated with PCV7. The number of children colonized with pneumococcus is shown. The percentage of children colonized is shown in parentheses.

  • c The odds ratio (OR), the 95% confidence interval (95% CI) for the odds ratio (shown in parentheses), followed by the P value.

  • d The adjusted odds ratio (aOR) for pneumococcal colonization was determined by multivariate logistic regression, controlling for race, smoking household contact, co-trimoxazole use, day care attendance, and mean age at the time of sample collection.